Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis

Company Overview

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company developing small-molecule medicines designed to selectively eliminate disease-causing proteins. The company uses its proprietary Tunable Molecular Glue (TME) platform to identify molecular glue degraders that redirect the cell’s natural protein-degradation machinery toward specific therapeutic targets.

Monte Rosa’s research and development programs address areas including autoimmune and inflammatory diseases, as well as cancer. Its pipeline has included MRT-6160, an orally administered molecular glue degrader designed to target VAV1, a protein involved in immune-cell signaling, and MRT-2359, a degrader targeting GSPT1 for potential use in oncology. The company continues to evaluate and advance its most promising programs through clinical development.

Founded in 2018 and headquartered in Boston, Massachusetts, Monte Rosa conducts drug discovery and clinical-development activities through operations and collaborations serving the global biopharmaceutical market. The company’s common stock trades on the Nasdaq under the symbol GLUE.

Key Stats

• Today's Range: $11.62 to $11.89
• 50-Day Range: $11.72 to $23.79
• 52-Week Range: $6.53 to $25.77
• Volume: 802,135 shs
• Average Volume: 1.13 million shs
• Market Capitalization: $1.00 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.50
• Consensus Rating: Moderate Buy

Monte Rosa Therapeutics Stock Analysis - MarketRank™

Monte Rosa Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 649th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Monte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Monte Rosa Therapeutics has a consensus price target of $28.50, representing about 142.1% upside from its current price of $11.77.

Amount of Analyst Coverage

Monte Rosa Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Monte Rosa Therapeutics are expected to decrease in the coming year, from ($1.04) to ($1.34) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Monte Rosa Therapeutics is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Monte Rosa Therapeutics is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Monte Rosa Therapeutics has a P/B Ratio of 3.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.13% of the float of Monte Rosa Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 17.08, which indicates bearish sentiment.

Change versus previous month

Short interest in Monte Rosa Therapeutics has recently increased by 6.58%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Monte Rosa Therapeutics does not currently pay a dividend.

Dividend Growth

Monte Rosa Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.61

News Sentiment

Monte Rosa Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Monte Rosa Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for GLUE on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Monte Rosa Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $641,132.00 in company stock.

Percentage Held by Insiders

6.40% of the stock of Monte Rosa Therapeutics is held by insiders.

Percentage Held by Institutions

79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/27/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GLUE
• CIK: 1826457
• Web: www.monterosatx.com
• Phone: 617-949-2643
• Fax: N/A
• Employees: 173
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Monte Rosa Therapeutics: $28.50
• High Price Target: $37.00
• Low Price Target: $25.00
• Potential Upside/Downside: +142.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.63 million
• Net Margins: -560.85%
• Pretax Margin: -570.80%
• Return on Equity: -43.31%
• Return on Assets: -27.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.58
• Quick Ratio: 10.58

Sales & Book Value

• Annual Sales: $123.67 million
• Price / Sales: 8.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.58 per share
• Price / Book: 3.29

Miscellaneous

• Outstanding Shares: 85,310,000
• Free Float: 79,853,000
• Market Cap: $1.00 billion
• Optionable: Optionable
• Beta: 1.50